Today: 29 April 2026
Browse Category

NASDAQ:GRAL 3 October 2025 - 27 February 2026

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.
20 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAL shares surged to $69.14 intraday on Oct 3, up nearly 6.8% and about 248% year-to-date. Market cap reached $2.3–2.5 billion, a 472% jump since mid-2024, despite ongoing losses and negative EPS. Wall Street consensus remains “Hold” with a $31.50 average price target, far below current levels. Investors await new PATHFINDER 2 trial data at ESMO Congress later this month.
3 October 2025
···

Stock Market Today

  • Smart Share Global Withdraws ADS Listing from Nasdaq
    April 29, 2026, 1:50 PM EDT. Smart Share Global Ltd has formally withdrawn its American Depositary Shares (ADS) listing from the Nasdaq Stock Market. The move was confirmed through the filing of Form 25 with the U.S. Securities and Exchange Commission, which notifies the removal of a security from exchange listing and registration. Nasdaq executed the delisting based on regulatory compliance provisions under the Securities Exchange Act of 1934. Smart Share Global, headquartered in Shanghai, China, did not disclose detailed reasons behind the withdrawal. This development marks a significant shift for the Chinese firm's market presence in the United States, raising questions about future listing strategies or market focus.

Latest article

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

29 April 2026
Sagtec Global reported 2025 audited revenue of $19.1 million, up 49%, driven by strong growth in services. Shares surged 38% to $2.35 in U.S. trading after volatile swings. Operating income dropped 9% to $2.1 million and earnings per share fell to $0.09 from $0.16, reflecting higher costs after the Nasdaq IPO. Net cash from operations rose 187% to $4.1 million.
Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

29 April 2026
The Dow Jones Industrial Average dropped 320 points, or 0.65%, to 48,821.82 Wednesday afternoon, heading for a fifth straight loss as investors awaited the Federal Reserve’s rate decision and major tech earnings. Brent crude surged 7.14% to $119.20 after reports of a possible extended Iran blockade. Boeing and Goldman Sachs weighed on the Dow, while Amazon rose and Microsoft slipped in midday trading.
Go toTop